
TAG1, NRG Pallas sign LOI to expand lead-212 supply
The companies plan to combine TAG1’s portable lead-212 generator with NRG Pallas’ radium-224 production capabilities for cancer drug developers in Europe.
Section
M&A, vendor news, reimbursement, and the economics of imaging.

The companies plan to combine TAG1’s portable lead-212 generator with NRG Pallas’ radium-224 production capabilities for cancer drug developers in Europe.

The clearance covers Rembra CT for diagnostic imaging and 2 radiation therapy planning systems, Rembra RT and Areta RT.

The Novasight Hybrid System combines IVUS and OCT imaging in a single platform for intravascular imaging of coronary arteries.

The zero-footprint DICOM viewer has been rebranded as AdvaView and integrated with AdvaPACS, the company’s cloud-native imaging platform.

NorthStar is a cardiac mapping and guidance platform designed for real-time MR-guided interventional procedures.

The Lansing, MI-based particle accelerator company also completed a reverse merger with JDEV Acquisition.

The $585M deal adds CathWorks’ FFRangio system to Medtronic’s interventional cardiology portfolio.

The multiyear agreement will focus on MRI, photon-counting CT, targeted ultrasound, and AI-enabled PET/CT and MRI image analysis.

Relevant. Nanox.ARC is an FDA-cleared multisource digital tomosynthesis system intended to expand 3D imaging access across healthcare and public sector settings.

The deal gives Sectra ownership of ChestLink, Oxipit’s CE Class IIb-certified autonomous AI product for chest X-ray analysis.

Grau will become CEO on May 1, with Steve Corbeil moving to executive chairman of the board as part of a planned succession.

The funding will support product development and international expansion of ScreenPoint Medical’s Transpara breast AI solutions.

The approval covers Vueway injection, a macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI in adults and children 2 years and older.

Siemens plans to put the direct spin-off of Siemens Healthineers shares to a shareholder vote at its February 2027 Annual General Meeting.

The companies will co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Telix receiving $40M upfront and eligibility for up to $2.1B in milestones.